On December 26, 2024, the Supreme Court of Korea reversed the appellate court’s conviction of CMIT/MIT product manufacturers, citing chemical differences between PHMG products and independent development. However, both products shared identical exposure routes (inhalation), target organs (lungs), and vulnerable populations. All manufacturers failed to assess inhalation toxicity and concealed ingredients. Scientific evidence established CMIT/MIT’s pulmonary toxicity through clinical cases of severe lung injury from CMIT/MIT-only exposure, cellular toxicity studies, and epidemiological evidence of synergistic interactions with PHMG. While the appellate court integrated toxicological, epidemiological, and clinical evidence, the Supreme Court neither evaluated CMIT/MIT’s toxicity nor addressed co-exposure scenarios, effectively applying scientific uncertainty in favor of manufacturers. The ruling exposed structural limitations in the current criminal law system regarding environmental health disasters. In the remanded trial, liability for single-exposure victims should be clearly established. For the 94 co-exposure victims, the evidentiary standard is critical: If courts demand precise quantitative attribution per substance—which is scientifically infeasible due to synergistic interactions and individual variability—this may paradoxically preclude victim relief despite sufficient evidence. However, liability can be established if substantial contribution suffices. Systemic reforms including abolishing statutes of limitations for environmental crimes and expanding judicial scientific advisory systems are urgently needed.
Ⅰ. 배 경
Ⅱ. 대법원 판결의 논리 구조와 법리적 한계
Ⅲ. CMIT/MIT의 독성에 대한 과학적 증거와 법원의 평가
Ⅳ. 환송심에서의 과제
Ⅴ. 환경보건 참사 대응을 위한 사법제도 개선 과제
Ⅵ. 맺음말
References
(0)
(0)